Recent Drug Approvals from the US FDA and EMEA: What the Future Holds
- 1 April 2009
- journal article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 1 (1) , 35-48
Abstract
The decreased productivity of the pharmaceutical industry in terms of new medical entities approved by the US FDA and the European Medicines Agency (EMEA) on a yearly basis has long been debated. This review will analyze overall new drug applications (NDAs) approved by both the FDA and EMEA in 2007, with the aim of finding trends (also looking at the past) that can be used to predict what the future may be. After a general introduction to the regulatory terminology, NDA approvals in 2007 are divided into categories (new applications of old medicines, metabolites, enantiomers and prodrugs, biological products, natural products and small organic molecule new molecular entities) and discussed. General aspects of the NDA approvals, such as historical trends, the length of the drug-discovery process, geography, differences among therapeutic areas, and the relative role of biotech and pharma industries are also outlined. From this analysis, a perspective is gained on some aspects that will probably influence fu...Keywords
This publication has 12 references indexed in Scilit:
- 2008 FDA drug approvalsNature Reviews Drug Discovery, 2009
- Aliskiren: the first renin inhibitor for clinical treatmentNature Reviews Drug Discovery, 2008
- Drug approvals and failures: implications for alliancesNature Reviews Drug Discovery, 2008
- 2007 FDA drug approvals: a year of fluxNature Reviews Drug Discovery, 2008
- RetapamulinNature Reviews Drug Discovery, 2007
- What's fueling the biotech engine?Nature Biotechnology, 2007
- Natural Products as Sources of New Drugs over the Last 25 YearsJournal of Natural Products, 2007
- Why is cancer drug discovery so difficult?Nature Reviews Drug Discovery, 2006
- An update on the first decade of the European centralized procedure: how many innovative drugs?British Journal of Clinical Pharmacology, 2006
- The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS2005